Clinical trials: Sense of Control
Hearing Loss
Tuned App Self-Fitting vs. Professional Fitting
The aim of the study is to compare the perceived outcome of the self-fitting performed by the participants using the Tuned mobile application with the traditional professional fitting as performed by a licensed professional…
- Trial name
- NCT05869266
- Testing
- professional fitting vs. self fitting
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Tuned Ltd.
Hearing Loss
Evaluation of the Presence of SENS-401 in the Perilymph
The aim of this study is to detect the presence of SENS-401 in the perilymph of participants undergoing cochlear implant surgery after 7 days of oral administration of SENS-401.
- Trial name
- NCT05258773
- Testing
- SENS-401 (R-Azasetron Besylate)
- Where
- 7 sites in Australia, France
- Volunteers
- 28 people
- Sponsor
- Sensorion
Subjective Tinnitus
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
- Trial name
- NCT00955799
- Testing
- Neramexane mesylate
- Where
- 76 sites in United States, Austria and 3 more
- Volunteers
- 455 people
- Sponsor
- Merz Pharmaceuticals GmbH
Tinnitus, Subjective
OTO-313 in Subjects With Subjective Tinnitus
The purpose of this study is to evaluate the safety, tolerability, plasma pharmacokinetics (PK), and exploratory efficacy of OTO-313 administered as an intratympanic injection for the treatment of subjective tinnitus.
- Trial name
- NCT03918109
- Testing
- OTO-313
- Where
- 16 sites in United States
- Volunteers
- 43 people
- Sponsor
- Otonomy, Inc.
Sensorineural Hearing Loss, Noise Induced Hearing Loss
FX-322 in Adults With Stable Sensorineural Hearing Loss
This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322 compared to placebo in healthy male and female adults with stable sensorineural hearing loss.
- Conditions
- Sensorineural Hearing Loss, Noise Induced Hearing Loss, Sudden Sensorineural Hearing Loss
- Trial name
- NCT04120116
- Testing
- FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses)
- Where
- 16 sites in United States
- Volunteers
- 95 people
- Sponsor
- Frequency Therapeutics
Noise Induced Hearing Loss
A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss
SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL.
- Trial name
- PANIHL (NCT02779192)
- Testing
- SPI-1005 200mg, SPI-1005 400mg
- Where
- 5 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sound Pharmaceuticals, Incorporated
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT07498426
- Testing
- NIO752
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Urinary Tract Infection
Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection
PP4001 is a medication not yet approved by the US FDA. This is a phase 2, multi-center, randomized, double-blind study of 3 doses of PP4001 versus placebo in the treatment of symptoms associated with uncomplicated urinary tract…
- Trial name
- NCT01406587
- Testing
- PP4001
- Where
- 25 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pinnacle Pharmaceuticals, Inc.
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Hearing Loss
Quality Control of CE-Labelled Phonak Hearing Systems (Study Part: Sonova2015-00)
The purpose of this study, which contains a series of successive study parts, is to methodically evaluate Phonak Hearing Systems on hard of hearing participants to grant quality control prior to each product launch.
- Trial name
- NCT02754843
- Testing
- Phonak's equivalent newly developped power BTE, Equivalent competitor device
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Sonova AG
Hearing Loss, Sensorineural
Quality Control of CE-Certified Phonak Hearing Aids - 2017_37
Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner.
- Trial name
- NCT03379766
- Testing
- Successor of Phonak Audéo B-Direct, Phonak Audéo B-Direct
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Sonova AG
Diabetic Peripheral Neuropathy, Chronic Pain
Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy
Two Phase 1 studies have been conducted with AEG33773 and available safety and tolerability data from these studies support further clinical development of AEG33773.
- Trial name
- NCT00891683
- Testing
- AEG33773 oral dosing
- Where
- 20 sites in United States, Bulgaria and 2 more
- Volunteers
- 128 people
- Sponsor
- Aegera Therapeutics
Retinitis Pigmentosa, Retinitis
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases
- Trial name
- RESTORE (NCT04945772)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Nanoscope Therapeutics Inc.
Hearing Loss, Hearing Impairment
Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
The objective of this pilot study is to explore whether repeat doses of AUT00063 can provide an indication of improvement in performance of tests across a battery of speech and hearing assessments in cochlear implant users.
- Trial name
- NCT02832128
- Testing
- AUT00063
- Where
- 4 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Autifony Therapeutics Limited
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Hearing Loss, Deafness
Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
The purpose of this study is to determine whether ancrod is effective and safe in the treatment of sudden sensorineural hearing loss (SSHL).
- Conditions
- Hearing Loss, Deafness, Hearing Loss, Sensorineural, Hearing Disorders
- Trial name
- NCT01621256
- Testing
- Ancrod, Saline solution
- Where
- 7 sites in Czechia, Germany
- Volunteers
- 31 people
- Sponsor
- Nordmark Arzneimittel GmbH & Co. KG
Hyperalgesia, Neurodynia
GW406381 In Patients With Peripheral Nerve Injury
The findings from preclinical animal models confirm the peripheral anti-inflammatory/analgesic activity of GW406381 and also suggest contribution of a central site of action to the anti-hyperalgesic efficacy that may not be…
- Conditions
- Hyperalgesia, Neurodynia, Pain, Trauma
- Trial name
- NCT00279032
- Testing
- GW406381
- Where
- 5 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Subjective Tinnitus
Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
- Trial name
- NCT00772980
- Testing
- Neramexane mesylate
- Where
- 56 sites in Belgium, Czechia and 4 more
- Volunteers
- 400 people
- Sponsor
- Merz Pharmaceuticals GmbH
Presbycusis, Hearing Loss, Sensorineural
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with age-related sensorineural hearing loss.
- Conditions
- Presbycusis, Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
- Trial name
- NCT04601909
- Testing
- FX-322
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Frequency Therapeutics